

**Appendix 1. Characteristics of Trial Participants (Significant Bacteriuria Excluded)**  
**According to Randomization to Ondansetron or Metoclopramide**

	Ondansetron	Metoclopramide	<i>P</i>
	n = 72	n = 74	
Age (years)	29.5 ± 4.5	29.2 ± 4.4	0.65
Gestational age (weeks)	9.6 ± 2.3	9.4 ± 2.5	0.75
Gravidity	2 [1-3]	2 [1-3]	0.44
Parity	1 [0-2]	1 [0-2]	0.60
Parous	40 (55.6)	39 (52.7)	0.74
Number of Miscarriages	0 [0-0]	0 [0-0]	0.37
Any miscarriage	14 (19.4)	10 (13.5)	0.38
Ethnicity			
Malay	55 (76.4)	60 (81.8)	0.12
Indian	4 (5.6)	9 (12.2)	
Chinese	4 (5.6)	2 (2.7)	
Others	9 (12.5)	3 (4.1)	
Employed	53 (73.6)	61 (82.4)	0.23
Weight (kg)	56.9 ± 10.8	57.0 ± 10.9	0.93
Body Mass Index	23.5 ± 4.2	23.2 ± 4.0	0.72
Medical History	14 (19.4)	8 (10.8)	0.17

Abas MN, Tan PC, Azmi N, Omar SZ. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. *Obstet Gynecol* 2014;123.

The authors provided this information as a supplement to their article.

### At recruitment

Ketonuria (dipstick)			0.40
2+	15 (20.8)	11 (14.9)	
3+	13 (18.1)	10 (13.5)	
4+	44 (61.1)	53 (71.6)	
Nausea score <sup>†</sup>	8 [7-9]	8 [7-10]	0.18
Serum sodium (mmol/l)	136 ± 2	136 ± 2	0.32
Serum potassium (mmol/l)	3.9 ± 0.4	3.9 ± 0.4	0.58
Hematocrit	0.38 ± 0.03	0.38 ± 0.03	0.42

---

Data are mean ± standard deviation, median [interquartile range] or number (%) unless otherwise specified. Analysis is by Student t test for continuous variables, Mann Whitney U test for non-normally distributed or ordinal data and for categorical data the Fisher's exact test for 2 x 2 data sets and Chi Square test for larger categorical data sets.

\*Asthma (13), dyspepsia (3), cardiomyopathy (1), anaemia (1), lupus (1), epilepsy (1), essential hypertension (1) and hearing impairment (1).

<sup>†</sup>Nausea is self-scored by participants using a 10-point visual numerical rating score with a score of 1 to 10 (higher score more nausea).

Abas MN, Tan PC, Azmi N, Omar SZ. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. *Obstet Gynecol* 2014;123.

The authors provided this information as a supplement to their article.